Methods for the inhibition of neointima formation
US7048939B2 · kind B2 · utility
52Cited by
3References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 11, 2002 |
| Grant date | May 23, 2006 |
| Priority date | — |
| Expiry date | Oct 25, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/606
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
Restenosis is inhibited through local delivery of anti-restenotic agents including angiotensin converting enzyme inhibitors; nicotine receptor agonists, agents that increase concentrations of nitric oxide, anti-angiogenic agents, agonists of the TGF-beta receptor; death domain receptor ligands; and thrombin inhibitors. In one embodiment of the invention, the localized delivery is effected through the use of a stent modified for delivery of the agent at the site of injury from balloon angioplasty.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.